Cost-Effectiveness of Brentuximab Vedotin in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma in Taiwan
Nov 1, 2016, 00:00
10.1016/j.jval.2016.08.705
https://www.valueinhealthjournal.com/article/S1098-3015(16)31285-2/fulltext
Title :
Cost-Effectiveness of Brentuximab Vedotin in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma in Taiwan
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(16)31285-2&doi=10.1016/j.jval.2016.08.705
First page :
A811
Section Title :
Cost-Effectiveness Studies
Open access? :
No
Section Order :
2298